Skip to main content

Table 1 Linear regression to analyze cisplatin and/or compound's effect on OVCAR-3 cell proliferation.

From: Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc

 

Kaempferol

α-Tocopherol Succinate

Rutin Hydrate

R2

0.901

0.891

0.188

 

B

Sig.

B

Sig.

B

Sig.

Constant

2.002

0.000

2.010

0.000

2.009

0.000

Cisplatin

-0.012

0.198

-0.019

0.040

-0.028

0.789

Compound

-0.022

0.238

-0.048

0.006

-0.237

0.221

Cispl. × Comp.

-0.058

0.001

-0.032

0.015

0.029

0.844

 

Apigenin

Taxifolin

Luteolin

R2

0.947

0.415

0.841

 

B

Sig.

B

Sig.

B

Sig.

Constant

2.008

0.000

2.009

0.000

2.010

0.000

Cisplatin

-0.015

0.119

-0.028

0.035

-0.019

0.076

Compound

-0.173

0.000

-0.003

0.902

-0.102

0.000

Cispl. × Comp.

0.0080

0.571

0.003

0.884

0.008

0.548

 

Naringin

α-Tocopherol

Genistein

R2

0.296

0.541

0.885

 

B

Sig.

B

Sig.

B

Sig.

Constant

2.009

0.000

2.010

0.000

2.010

0.000

Cisplatin

-0.028

0.306

-0.019

0.521

-0.019

0.086

Compound

-0.058

0.243

-0.062

0.253

-0.117

0.000

Cispl. × Comp.

0.001

0.989

-0.046

0.269

0.0001

0.994

 

Quercetin

    

R2

0.567

    
 

B

Sig.

    

Constant

2.010

0.000

    

Cisplatin

-0.019

0.467

    

Compound

-0.029

0.533

    

Cispl. × Comp.

-0.056

0.134

    
  1. Data from 3 independent experiments were modeled as (Viability = Constant + Cisplatin + Compound + Cisplatin* Compound) to analyze effects of Cisplatin, Compound, and Cisplatin-Compound interactions. Tabulated are standardized coefficients (B) with corresponding p values (Sig.) for each model. The goodness of fit, R2, is also listed for each model.